CD34 and Miyoshi myopathy: Another phase II clinical trial of the KD (carfilzomib + dexamethasone) treatment for MM patients showed an average CD34+ stem cell collection of 12.70×106/kg(P>0.05), indicating that carfilzomib does not negatively affect hematopoietic stem cell mobilization (16).